RXDX:NSD-Prometheus Biosciences Inc (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 27.41

Change

0.00 (0.00)%

Market Cap

USD 1.82B

Volume

0.24M

Avg Analyst Target

USD 37.67 (+37.42%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Prometheus Biosciences Inc (RXDX) Stock Analysis:
Based on the Prometheus Biosciences Inc stock forecasts from 3 analysts, the average analyst target price for Prometheus Biosciences Inc is USD 37.67 over the next 12 months. Prometheus Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Prometheus Biosciences Inc is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Prometheus Biosciences Inc’s stock price was USD 27.41. Prometheus Biosciences Inc’s stock price has changed by -3.22 % over the past week, -8.05 % over the past month and +0.00 % over the last year.

About

Ignyta, Inc., a precision oncology biotechnology company, engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases. Its products pipeline includes entrectinib, a tyrosine kinase inhibitor d ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-04 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

USD61,525,874.67B 1.10 5.30
FTD FTD Companies, Inc

N/A

USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

N/A

USD24,651,104.38B 166.80 24.48
SNHY Helios Technologies, Inc

N/A

USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

USD8,997,243.52B 175.07 79.98
INSY INSYS Therapeutics, Inc

N/A

USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

USD38,513.36B N/A N/A

ETFs Containing RXDX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 338.56% 70% C- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 338.56% 70% C- 89% B+
Average Annual (5 Year Horizon)  
Capital Gain 91.77% 85% B 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 91.77% 85% B 92% A-
Risk Return Profile  
Volatility (Standard Deviation) 120.85% 32% F 13% F
Risk Adjusted Return 75.94% 86% B 86% B
Market Capitalization 1.82B 80% B- 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.30 56% F 73% C
Price / Cash Flow Ratio -20.21 84% B 81% B-
EV/EBITDA -82.64 89% B+ 100% A+
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -66.82% 21% F 13% F
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 31.15% 62% D- 49% F
Technical Ratios  
Short Ratio 3.00 60% D- 47% F
Short Percent 890.00% 25% F 1% F
Beta 1.88 29% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.